Cost–effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma

Autor:	Tanja Podkonjak, Holly Cranmer, Julia Scarisbrick, Grant McCarthy, Cameron Lilley, Lung-I Cheng
Rok vydání:	2022
Předmět:	Brentuximab Vedotin Skin Neoplasms Cost-Benefit Analysis Health Policy Humans State Medicine Lymphoma T-Cell Cutaneous
Zdroj:	Journal of Comparative Effectiveness Research. 11:193-202
ISSN:	2042-6313 2042-6305
Popis:	Aim: To assess the cost–effectiveness of brentuximab vedotin (BV) versus physician’s choice (methotrexate or bexarotene) for treating advanced cutaneous T-cell lymphoma. Materials & methods: A partitioned-survival model was developed from the National Health Service perspective in England and Wales. Model inputs were informed by the ALCANZA trial, real-world UK data, published literature or clinical experts. Results: Over the modeled lifetime, BV dominated physician’s choice and provided an additional 1.58 life-years and 1.09 higher quality-adjusted life years with a net cost saving of £119,565. The net monetary benefit was £152,326 using a willingness-to-pay threshold of £30,000/quality-adjusted life year. Results were robust in sensitivity and scenario analyses. Conclusion: BV is a highly cost-effective treatment for advanced cutaneous T-cell lymphoma.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3927c7614cbff90b7f5119112e1d3123 https://doi.org/10.2217/cer-2021-0201 Zobrazit plný text záznamu